Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

AstraZeneca

ClinicalTrials.gov Identifier:

NCT00098345

First received: December 7, 2004

Last updated: September 24, 2012

Last verified: September 2012

History of Changes

Results First Received: April 27, 2011

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Thyroid Cancer
Intervention:	Drug: ZD6474 (vandetanib)

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First patient enrolled 12 November 2004, last patient enrolled 15 August 2006, cut off date 22 February 2008

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Caprelsa (Vandetanib) 300 mg	Daily oral dose of Caprelsa (vandetanib) 300mg

Participant Flow: Overall Study

	Caprelsa (Vandetanib) 300 mg
STARTED	30
COMPLETED	17 ^[1]
NOT COMPLETED	13
Adverse Event	7
Withdrawal by Subject	2
progression	4

[1]	ongoing study treatment at data cut-off

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Caprelsa (Vandetanib) 300 mg	Daily oral dose of Caprelsa (vandetanib) 300mg

Baseline Measures

	Caprelsa (Vandetanib) 300 mg
Number of Participants [units: participants]	30
Age [units: years] Mean ( Full Range )	48.7 ( 20 to 77 )
Gender [units: Participants]
Female	21
Male	9

Outcome Measures

Show All Outcome Measures

1. Primary:

Objective Response Rate [ Time Frame: Pre-dose and every 12 weeks up to RECIST progression as defined according to RECIST 1.0. ]

Show Outcome Measure 1

2. Secondary:

Progression Free Survival [ Time Frame: Pre-dose and every 12 weeks up to RECIST progression as defined according to RECIST 1.0. ]

Show Outcome Measure 2

3. Secondary:

Duration of Objective Response [ Time Frame: Pre-dose and every 12 weeks up to RECIST progression as defined according to RECIST 1.0. ]

Show Outcome Measure 3

4. Secondary:

Disease Control Rate [ Time Frame: Pre-dose and every 12 weeks up to RECIST progression as defined according to RECIST 1.0. ]

Show Outcome Measure 4

5. Secondary:

Biochemical Response Calcitonin (CTN) [ Time Frame: Blood samples for analysis of CTN taken on Day 1 (every 3 hours for 24 hours), then a single sample on Day 5, weekly through the first 2 assessment periods, monthly (prior to amendment 7) and every 12 weeks (following amendments) until discontinuation ]

Show Outcome Measure 5

6. Secondary:

Symptomatic Response [ Time Frame: Symptomatic diarrhea was assessed using stool frequency and consistency diaries. Baseline was established using the average of the 4 days immediately prior to first dose on Day 5. Diaries were completed every day for the first 6 months on study drug. ]

Show Outcome Measure 6

7. Secondary:

World Health Organisation (WHO) Performance Status [ Time Frame: Performance status was assessed using the WHO criteria at baseline and because SD lasting for at least 24 weeks was used in the definition of disease control (in addition to confirmed objective response), WHO PS at 24 weeks was evaluated. ]

Show Outcome Measure 7

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Gerard Lynch
Organization: AstraZeneca
e-mail: aztrial_results_posting@astrazeneca.com

No publications provided

Responsible Party:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00098345 History of Changes
Other Study ID Numbers:	D4200C00008
Study First Received:	December 7, 2004
Results First Received:	April 27, 2011
Last Updated:	September 24, 2012
Health Authority:	United States: Food and Drug Administration

To Top